NasdaqGS - Nasdaq Real Time Price USD

InflaRx N.V. (IFRX)

0.7840

-0.0160

(-2.00%)

At close: June 13 at 4:00:01 PM EDT

0.7814

-0.00

(-0.33%)

After hours: June 13 at 7:16:20 PM EDT

COVID’s remaining biotech contenders navigate a dwindling market

With policy and funding evolving, companies are being forced to rethink strategies.

Pharma Voice 12 days ago

IVVD

IFRX
-2.00%
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility. This recommendation was based on data analysis of the first 30 patients enrolled in t

GlobeNewswire 17 days ago

IFRX
-2.00%
InflaRx to Participate in Upcoming Investor Conferences

JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025. Jefferies Global Healthcare ConferenceJune 3 - 5, 2025 in New York, NY InflaRx will conduct an investor presentation on June 4th at 7:35 AM ET and will participate in one-on-one investor meetings. A link to regi

GlobeNewswire 22 days ago

IFRX
-2.00%
InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)

InflaRx ( NASDAQ:IFRX ) First Quarter 2025 Results Key Financial Results Net loss: €8.31m (loss narrowed by 14% from 1Q...

Simply Wall St. last month

IFRX
-2.00%
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline addressing multiple sizable marketsInterim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG), to determine trial size adaptation or futility, remains on schedule with a recommendation expected to be announced at the end of May to e

GlobeNewswire last month

IFRX
-2.00%
InflaRx to Report First Quarter 2025 Results on May 7, 2025

JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and a

GlobeNewswire last month

IFRX
-2.00%
Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where InflaRx (NASDAQ:IFRX) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness. According to a report published by Roland […]

Insider Monkey 2 months ago

IFRX
-2.00%
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 2 months ago

IFRX
-2.00%
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurati

GlobeNewswire 2 months ago

IFRX
-2.00%
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses. These data are being presented at the 2025 Americ

GlobeNewswire 3 months ago

IFRX
-2.00%
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL. Camilla Chong, MD, Chief Medical Officer of InflaR

GlobeNewswire 3 months ago

IFRX
-2.00%
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned. InflaRx also announced that it will participate in two investor conferences. Details are as follows: Leerink Global Healthcare ConferenceMarch

GlobeNewswire 3 months ago

IFRX
-2.00%
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten public offering of 8,250,000 ordinary shares of the Company at a public offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company’s ordinary shares

GlobeNewswire 3 months ago

IFRX
-2.00%
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten public offering of 8,250,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company’s ordinary shares. The purchas

GlobeNewswire 3 months ago

IFRX
-2.00%
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company’s ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at wh

GlobeNewswire 3 months ago

IFRX
-2.00%
Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch

The U.S. stock market has recently experienced volatility, driven by trade policy uncertainties and fluctuating corporate results, with tariffs on Mexico being delayed as a temporary relief. Amidst this backdrop, penny stocks continue to attract attention for their potential to offer growth opportunities in smaller or emerging companies. While the term "penny stocks" may seem outdated, these investments can still provide value when backed by strong financial health and a clear growth trajectory.

Simply Wall St. 4 months ago

ANL

IFRX
-2.00%

INUV
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to di

GlobeNewswire 4 months ago

IFRX
-2.00%
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS

The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant.

Pharmaceutical Technology 4 months ago

IFRX
-2.00%
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS.

Zacks 4 months ago

IFRX
-2.00%
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care

GlobeNewswire 4 months ago

IFRX
-2.00%

Performance Overview

Return	IFRX	S&P 500 (^GSPC)
YTD	-68.26%	+1.62%
1-Year	-48.42%	+10.00%
3-Year	-38.99%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InflaRx N.V. (IFRX)

COVID’s remaining biotech contenders navigate a dwindling market

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

InflaRx to Participate in Upcoming Investor Conferences

InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Performance Overview